Last reviewed · How we verify
NCT05235607
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
Phase 1 trial testing Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration in Carcinoma in 60 participants. Status unknown.
1 June 2023
Quick facts
| Lead sponsor | Sichuan University |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 March 2022 |
| Primary completion | 1 June 2023 |
| Estimated completion | 2 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration — full drug profile →
Conditions studied
- Carcinoma — all drugs for Carcinoma →
- Melanoma — all drugs for Melanoma →
- Bladder Cancer — all drugs for Bladder Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Sichuan University
Who can join
Adults 18 to 75, any sex, with Carcinoma or Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal cancer. Then, we intended to explore the safety and efficacy of individual tumor antigen-sensitized DC vaccine and their sensitized T cells in these solid cancers.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x -
Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395 -
Dendritic cell subsets and implications for cancer immunotherapy.
Chen MY, Zhang F, Goedegebuure SP, Gillanders WE. · · 2024 · cited 24× · PMID 38903502 · DOI 10.3389/fimmu.2024.1393451 -
Personalised neoantigen-based therapy in colorectal cancer.
Zhu YJ, Li X, Chen TT, Wang JX, et al · · 2023 · cited 20× · PMID 37921274 · DOI 10.1002/ctm2.1461 -
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876 -
Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.
Martinis E, Ricci C, Trevisan C, Tomadini G, et al · · 2023 · cited 5× · PMID 37514155 · DOI 10.3390/pharmaceutics15071969 -
Recent research progress and clinical status of immunotherapy for colorectal cancer.
Huo Z, Liu G, Li J. · · 2026 · cited 4× · PMID 40619123 · DOI 10.1016/j.jare.2025.06.089 -
Research and Clinical Progress of Therapeutic Tumor Vaccines.
Dong C, Li Z, Tan D, Sun H, et al · · 2025 · cited 3× · PMID 40733649 · DOI 10.3390/vaccines13070672
Verify or expand the search:
- PubMed search for NCT05235607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carcinoma
Currently open trials in the same condition.
- NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
- NCT06969534 — Safety and Efficacy of Pucotenlimab in pLECC · Phase 2 · recruiting
- NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
- NCT07470827 — Evaluation of 'WAYMED Endo CL CS' for Automated Detection and Diagnosis of Colorectal Adenoma and Non-Adenoma Lesions · active not recruiting
- NCT06317311 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recu · Phase 2 · active not recruiting
Other Sichuan University trials
Trials by the same sponsor.
- NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
- NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05235607 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan University
- Last refreshed: 11 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05235607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing